(26) reported that sintilimab plus docetaxel as second-line therapy of advanced NSCLC without targetable mutation achieved median PFS of 4.5 and 2.6 months for PD-L1 (<1%)/CD8 (≥1%) and PD-L1 (<1%)/CD8 (<1%), respectively. This evidence concerns the gene CD8A and non-small cell lung carcinoma.